ReportsnReports.com adds “Advair (Asthma) – Forecast and Market Analysis to 2023” report to its research database.
Dallas, TX -- (SBWIRE) -- 09/19/2014 -- Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate. Salmeterol xinafoate is a highly selective LABA.
Complete Report Details
New PharmaPoint Drug Evaluation report, "Advair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Order a Purchase copy
-Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on Advair including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for Advair for the top eight countries from 2013 to 2023.
-Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Reasons to Buy:
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Asthma
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of Advair performance
-Obtain sales forecast for Advair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.4 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.2 Strategic Competitor Assessment
6 Advair (fluticasone propionate/salmeterol xinafoate)
6.4 SWOT Analysis
7.4 Forecasting Methodology
7.4.1 Diagnosed Asthma Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 About the Authors
7.6.4 Global Head of Healthcare
7.7 About GlobalData
Browse more reports on Pharmaceuticals Market